MSK radiation oncologist Paul Romesser

Paul Romesser, MD

Radiation Oncologist & Early Drug Development Specialist

Areas of Expertise

Conditions I Treat

  • Anal cancer
  • Rectal cancer
  • Metastatic cancers

My Specialties

  • Radiation therapy
  • Clinical trials
View all expertise
Dr. Romesser's Office Information
Languages: English
Request an Appointment
Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.
Back to top
English
Share

Get to Know Me

Hello, I am Dr. Paul Romesser, a board-certified radiation oncologist specializing in the treatment of rectal and anal cancer. I understand that that facing these types of cancer can be overwhelming, but please know I am here to provide you and your family with compassionate care and unwavering support throughout your journey.

As the Director of Colorectal and Anal Cancer Radiation Oncology, my experience and leadership in this specialized field position me as a trusted authority in the treatment of these cancers. I am deeply committed to helping patients like you navigate the complexities of cancer care and work with you to create comprehensive treatment plans tailored to your specific needs and circumstances. Together, we will work towards the best possible outcome; your well-being is our top priority.

Read more

At Memorial Sloan Kettering Cancer Center, we believe in taking a collaborative and multidisciplinary approach (care involving experts across medical specialties) to cancer care. Working closely with surgical and medical oncologists, radiologists, and pathologists, I ensure that my patients receive the best care possible. I take great pride in the expertise of the team supporting my patients. I want my patients to feel assured that they are in the hands of a dedicated group of experts throughout their journey.

Patient education is of the utmost importance to me. I understand the significance of understanding your diagnosis and treatment options, and I will take the time to explain the role of radiation therapy in your overall treatment plan. My compassionate approach aims to address any concerns or questions you may have while empowering you with the knowledge needed to make informed decisions about your care.

In addition to my clinical practice, I am actively involved in groundbreaking research and clinical trials in cancer care. Sometimes, a new therapy or treatment method available in a clinical trial offers the best chance for cure. Patients who decide that a clinical trial is right for them have the opportunity to access cutting-edge treatments and contribute to the advancement of medical knowledge. I am passionate about pushing the boundaries of radiation oncology and believe that through research, we can uncover innovative solutions that will benefit patients like you.

Beyond my professional endeavors, I am driven by a genuine desire to make a positive impact on the lives of my patients and community. I volunteer on the board of the HPV Alliance and The Anal Cancer Foundation — two organizations dedicated to providing education and support for people with cancer. When I’m not working, I cherish the precious moments spent with my loving family and our dog, Easton.

I want you to feel reassured that when you visit my office, you are not just another patient, but someone who will receive personalized care and advocacy. Your journey towards healing is my top priority, and I am here to guide you every step of the way. With empathy, expertise, and unwavering support, I am dedicated to helping you work through the challenges of rectal and anal cancer while instilling hope and inspiring you to embrace the future with optimism. Together, we will conquer cancer and embark on a path to restored health and well-being.

What I Do at MSK

I'm a radiation oncologist, which is a cancer doctor with special training in using radiation therapy (RT) to treat cancer.

I'm an early drug development specialist, which is a scientist who tests new drugs to treat cancer. I have special training in research studies, also known as clinical trials.

  • Director of Colorectal and Anal Cancer, Department of Radiation Oncology
Areas of Expertise

Conditions I Treat

  • Anal cancer
  • Rectal cancer
  • Metastatic cancers
  • Pancreatic cancer
  • Liver cancer and conditions
  • Liver metastases
  • Stomach (gastric) cancer
  • Endocrine and neuroendocrine cancers and conditions
  • Gallbladder cancer
  • Bile duct cancer (cholangiocarcinoma)

My Specialties

  • Radiation therapy
  • Clinical trials
Education & Honors

Education

  • MD, Boston University School of Medicine

Residencies

  • Radiation Oncology - Memorial Sloan Kettering Cancer Center

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

Women talking
New Patients
Scheduling an appointment is easy. Click or call 800-525-2225— we’re available 24 hours a day, 7 days a week
Make an Appointment
Current Patients
Request an appointment by logging in to MSK MyChart or calling your Care Team. If you are not enrolled in MSK MyChart, ask your Care Team to send you an invitation. You can also go to MSK MyChart and select “Sign up now.”

Contact and Location

Dr. Romesser sees patients at one location.

Office Phone
Location
New York, NY
Memorial Sloan Kettering Cancer Center
1275 York Avenue New York NY 10065
Get Directions

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Collaborators doctors

See all Early Drug Development Service doctors

See all External Beam Radiotherapy Service, Manhattan doctors

See all Brachytherapy Service doctors

Clinical Trials

Read more
Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

View Dr. Romesser's Lab

Romesser PB, Cahlon O, Scher E, Zhou Y, Berry SL, Rybkin A, Sine KM, Tang S, Sherman EJ, Wong R, Lee NY. Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. Radiotherapy and Oncology. 2016; 118(2):286-292. PMID 26867969.

Read more

Romesser PB, Cahlon O, Scher ED, Hug EB, Sine K, DeSelm C, Fox, JL, Mah D, Garg, MK, Chang J, Lee NY. Proton beam re-irradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. International Journal of Radiation Oncology Biology, and Physics. 2016; 95(1):386-395. PMID: 27084656.

Romesser PB, Romanyshyn JC, Schupak KD, Setton J, Riaz N, Wolden SL, Gelblum DY, Sherman EJ, Kraus D, Lee NY. Percutaneous endoscopic gastrostomy in oropharyngeal cancer patients treated with intensity-modulated radiotherapy with concurrent chemotherapy.  Cancer. 2012; 118(24):6072-6078. PMID 22707358.

Romesser PB, Sherman EJ, Shaha AR, Lian M, Wong RJ, Sabra M, Rao SS, Fagin JA, Tuttle RM, Lee NY. External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. Journal of Surgical Oncology. 2014; 110(4):375-382. PMID 24961938.

Romesser PB, Lim R, Spratt DE, Setton J, Riaz N, Lok B, Sherman EJ, Schoder H, Lee NY. The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pretreatment 18F-fluorodeoxyglucose positron emission tomography scan. Oral Oncology. 2014; 50(9):802-808. PMID 25043882.

Publications on PubMed

Visit PubMed for a full listing of Dr. Romesser’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Paul Romesser discloses the following relationships and financial interests:

  • 10x Genomics
    Professional Services and Activities (Uncompensated)
  • EMD Serono, Inc
    Professional Services and Activities
  • Faeth Therapeutics, Inc
    Professional Services and Activities
  • HPV Alliance
    Professional Services and Activities
  • HPV and Anal Cancer Foundation
    Professional Services and Activities (Uncompensated)
  • Natera Inc.
    Professional Services and Activities
  • XRad Therapeutics
    Professional Services and Activities (Uncompensated)

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures

Related topics: